Ketamineone Capital Limited Stock Net Income
Fundamental analysis of KetamineOne Capital allows traders to better anticipate movements in KetamineOne Capital's stock price by examining its financial health and performance throughout various phases of its business cycle.
KetamineOne |
KetamineOne Capital Limited Company Net Income Analysis
KetamineOne Capital's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current KetamineOne Capital Net Income | (25.21 M) |
Most of KetamineOne Capital's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, KetamineOne Capital Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, KetamineOne Capital Limited reported net income of (25.21 Million). This is 107.39% lower than that of the Healthcare sector and significantly lower than that of the Medical Care Facilities industry. The net income for all United States stocks is 104.41% higher than that of the company.
KetamineOne Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses KetamineOne Capital's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of KetamineOne Capital could also be used in its relative valuation, which is a method of valuing KetamineOne Capital by comparing valuation metrics of similar companies.KetamineOne Capital is currently under evaluation in net income category among its peers.
KetamineOne Fundamentals
| Return On Equity | -6.56 | |||
| Return On Asset | -0.8 | |||
| Operating Margin | (3.89) % | |||
| Current Valuation | 1.82 M | |||
| Shares Outstanding | 129.97 M | |||
| Price To Book | 0.95 X | |||
| Price To Sales | 6.74 X | |||
| Revenue | 6.44 M | |||
| Gross Profit | 424.24 K | |||
| EBITDA | (24.3 M) | |||
| Net Income | (25.21 M) | |||
| Cash And Equivalents | 315.2 K | |||
| Total Debt | 2.13 M | |||
| Debt To Equity | 2.18 % | |||
| Current Ratio | 0.26 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (3.64 M) | |||
| Earnings Per Share | (0.33) X | |||
| Beta | 1.09 | |||
| Market Capitalization | 64.6 M | |||
| Z Score | 18.0 |
About KetamineOne Capital Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze KetamineOne Capital Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of KetamineOne Capital using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of KetamineOne Capital Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in KetamineOne Pink Sheet
KetamineOne Capital financial ratios help investors to determine whether KetamineOne Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in KetamineOne with respect to the benefits of owning KetamineOne Capital security.